Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), an exciting biotech out of Massachusetts, is breaking ground with their barocyclers, microtubes, isolation kits and proprietary Pressure Cycling Technology (PCT) – a platform with more life science applications than any layperson could ever dream of. Currently, the company trades at $0.21 per share with a market cap of $2.24 million. And, anyone who suggests that PBIO is significantly undervalued…is exactly right. Expect PBIO to become a household name (in a laboratory worth its salt that is) within a period of months.
Understandably, infectious microorganisms are fairly difficult to pin down even for most of today’s state-of-the-art molecular-based diagnostic methods. Headaches inevitably arise as scientists strive for a safe sample preparation of potentially harmful substances while simultaneously trying to preserve the sample’s molecular integrity. This is why, with PCT and their Shredder SG3 System, PBIO has virtually no competition. And, now that their product is sufficiently honed and singular, the company aims to shift from development toward sales and marketing. With a recent focus on DNA detection and decontamination, it seems there is no molecule to elusive for PCT, and we expect this miracle product to become increasingly visible over the next year and a half.
In a recent interview with Harry Norman of Proactive Investors, Pressure BioSciences’ CEO Richard Schumacher (formerly the head of three companies with combined market caps of over $1 billion) assured investors of his long-term confidence in the aspiring pressure cycling company and said that the time had come for PBIO to launch an aggressive and comprehensive commercialization plan. Now, let’s take a look at how they are making good on that promise.
On the heels of good news about increased DNA detection in forensic samples, not to mention a 70 percent revenue growth for the second consecutive quarter, PBIO has continued to add top level clients, expand their strategic partnerships and widen an overseas distribution network. On November 7, 2012, Cole-Parmer (a worldwide leader in providing equipment and consumables to labs) announced that they had signed a Supplier Agreement, under which it will distribute the PBI Shredder SG3 System and processing tubes on a non-exclusive basis.
In addition, the company will also be a focus of the keynote address at the opening ceremony of this year’s ClinMicro – a veritable jamboree of biotech bigwigs with a mix of microbiologists, microbial Genomics experts, leading companies and powerful academics from around the world. It was announced on Halloween Day that Dr. Bradford Powell, President of Cernomics Solutions, would present PBIO and PCT in his keynote address and in another main session presentation later in the conference being held at the Hilton San Antonio Airport starting November 12.
Before ClinMicro, Dr. Powell talked up PCT saying, “It has already been demonstrated that the PCT Platform has the ability to inactivate and extract live attenuated virus and bacteria that are used as models of important biological threat agents. To that end, protein and nucleic acid markers from Venezuelan Equine Encephalitis virus and Bacillus anthracis (Sterne) spores were processed in less than an hour, as safely and as effectively as conventional procedures that often require more time, as well as large investments for facilities infrastructure, training, and oversight. Consequently, we are confident that the PCT Platform has the potential to provide an adaptable, cost-effective solution for advancing the capability, safety, and performance of assays used in the clinical and microbial genomics sciences. This is a transformative technology whose time, we believe, has come for broad application and acceptance.”
Dr. Powell is absolutely correct. The possibilities of PCT are almost limitless. The technology could already improve test samples, aid clinical laboratory medicine, and improve healthcare across the globe. Embracing this microbiological advancement means simplifying the job of people who track criminals and catching a potentially harmful virus where we wouldn’t have otherwise looked. It means stopping contaminated low-quality food before something like “pink slime” reaches our children’s school lunch line. And, these endeavors seem more than worthy of federal funding, scientific sponsorship or some such hefty investment. In other words, the FBI already has use for PCT’s capabilities, and so does the FDA, the USDA, and the CDC, so it seems only a matter of time before its use becomes widespread. Either way, we’d keep a watchful eye on this fascinating and promising small cap. Perhaps Dr. Nate Lawrence, Vice President of Sales and Marketing of PBI, summed up PBIO’s current situation best with this recent comment:
“We believe that this increased understanding of infectious microbes and microbial genomics, aided by the use of our novel PCT Platform, will accelerate the development of improved diagnostics, therapeutics, and food safety measures. We also believe that these clear sample-processing advantages will continue to compel researchers to integrate the PCT Platform into their basic scientific studies and clinical applications, resulting in measurable revenue growth and product visibility for Pressure BioSciences, Inc.”